Abstract:Background Developing innovative drugs with potent efficacy, specificity, and high safety remains an ongoing task in antitumor therapy development. In the last few years, peptide drugs have become attractive agents in cancer therapy. HM-3, mainly with antiangiogenic effect, and AP25, with an additional antiproliferative effect, are two peptides designed in our laboratory targeting αvβ3 and α5β1 integrins, respectively. The low molecular weight of the two peptides renders their recombinant expression very difficult, and the complicated structure of AP25 makes its chemical synthesis restricted, which presents a big challenge for its development. Methods Bifunctional peptides designed by the ligation of HM-3 and AP25, using linkers with different flexibility, were prepared using recombinant DNA technology in Escherichia coli. The fusion peptides were expressed in a modified auto-induction medium based on a mixture of glucose, glycerol, and lactose as carbon substrates and NH4+ as nitrogen source without any amino acid or other elements. Subsequently, the antiangiogenic, antiproliferative, and cell adhesion assays were conducted to evaluate the bioactivity of the two fusion peptides. Results The peptides were successfully expressed in a soluble form without any induction, which allows the culture to reach higher cell density before protein expression occurs. Human umbilical vein endothelial cell migration assay and chick embryo chorioallantoic membrane assay showed, at low doses, a significantly increased antiangiogenic effect (>75%) of the purified products compared with the single molecules. Meanwhile, MTT assay confirmed their enhanced antitumor activity against gastric cancer cell line MGC-803; however, no significant effect was observed on hepatoma HepG2 cells and no cytotoxicity on normal human lens epithelial cell SRA01/04 and human epithelial esophageal cells. Conclusion Bifunctional molecules with antiangiogenic and antiproliferative effects were obtained by using this technique, which presents an alternative for small peptide production, instead of the conventional chemical method. The increased molecular weight facilitates the peptide expression with a simultaneous improvement in their stability and biological activity.

Chemically Synthesized Matrix Metalloproteinase and Angiogenesis-Inhibiting Peptides As Anticancer Agents.

Generation of antitumor peptides by connection of matrix metalloproteinase-9 peptide inhibitor to an endostatin fragment.

An Artificial Mirna Against Hpse Suppresses Melanoma Invasion Properties, Correlating With A Down-Regulation Of Chemokines And Mapk Phosphorylation

Matrix metalloproteinase 2‐responsive dual‐drug‐loaded self‐assembling peptides suppress tumor growth and enhance breast cancer therapy

Molecular Mechanism of Pancreatic Tumor Metastasis Inhibition by Gd@C82(OH)22 and Its Implication for De Novo Design of Nanomedicine.

Novel Production Method of Innovative Antiangiogenic and Antitumor Small Peptides in Escherichia Coli

An engineered TIMP2-based and enediyne-integrated fusion protein for targeting MMP-14 shows potent antitumor efficacy

Engineered Peptide Macrocycles Can Inhibit Matrix Metalloproteinases with High Selectivity.

Advances in Clinical Research of Matrix Metalloproteinase Inhibitors as Anticancer Agents

Dual-targeting anti-angiogenic cyclic peptides as potential drug leads for cancer therapy

Tumor-Targeted Cell-Penetrating Peptides Reveal That Monomethyl Auristatin E Temporally Modulates the Tumor Immune Microenvironment

Targeting Matrix Metalloproteinases And Endothelial Cells With A Fusion Peptide Against Tumor

An Rgd-Modified Endostatin-Derived Synthetic Peptide Shows Antitumor Activity In Vivo

Matrix Metalloproteinases-2/9-sensitive Peptide-Conjugated Polymer Micelles for Site-Specific Release of Drugs and Enhancing Tumor Accumulation: Preparation and in Vitro and in Vivo Evaluation

Intelligently Targeted Drug Delivery and Enhanced Antitumor Effect by Gelatinase-Responsive Nanoparticles

Advances and Prospects of Anginex As a Promising Anti-Angiogenesis and Anti-Tumor Agent.

Discovery of Phenolic Matrix Metalloproteinase Inhibitors by Peptide Microarray for Osteosarcoma Treatment

Therapeutic Targeting of Angiogenesis with a Recombinant CTT Peptide–Endostatin Mimic–Kringle 5 Protein

Enzyme-Activatable Interferon–Poly(α-amino Acid) Conjugates for Tumor Microenvironment Potentiation

Translocating a High-Affinity Designer TIMP-1 to the Cell Membrane for Total Renal Carcinoma Inhibition: Putting the Prion Protein to Good Use

RGD-modified endostatin fragments showed an antitumor effect through antiangiogenesis.